10-Q · May 6, 2026
Accuray reported a challenging Q3 2026 with a total net revenue of $104.8 million, falling short of the $111.9 million estimate, and a diluted EPS loss of $0.09, exceeding the expected loss of $0.04. Geopolitical…
Earnings analysis · 10-K
ARAY earnings analysis
Filed August 27, 2026 · Our reading of the company's report
The latest report
Accuray retains a differentiated CyberKnife and helical radiation-therapy strategy, with product positioning centered on adaptive radiotherapy, motion management, software and recurring services. However, fiscal 2026…
Read full summary
Accuray retains a differentiated CyberKnife and helical radiation-therapy strategy, with product positioning centered on adaptive radiotherapy, motion management, software and recurring services. However, fiscal 2026 revenue fell 12% to $401.947 million, gross margin declined to 27.7%, net loss widened to $49.194 million and operating cash flow turned negative at $6.981 million, driven especially by a 45% decline in China revenue and lower product shipments. The proposed $55.0 million preferred financing and covenant holiday may provide liquidity support, but closing conditions, substantial potential dilution, high debt costs and an unremediated material weakness create significant downside risk.
From revenue to operating profit
Where each $100 of revenue went in this report.
Cost of sales, operating expenses, and what remained. Figures are rounded to whole dollars.
Where revenue came from
The business segments reported by the company.
Shares of the segments disclosed in this filing, largest first.
Reported figures
- Earnings per share
- $-0.4
What stood out
-
Differentiated radiation-therapy portfolio
Accuray is positioning CyberKnife and its helical portfolio around precision, motion management, adaptive radiotherapy and workflow efficiency. Its intellectual-property portfolio included 623 U.S. and foreign patents and 52 patent applications as of June 30, 2026.
-
Recurring services partly offset product decline
Services revenue increased 4% to $229.235 million and represented 57% of total revenue, supported by a larger installed base, higher contract renewal rates and higher out-of-contract billings. This partially offset the 27% decline in product revenue to $172.712 million.
-
Adaptive therapy and AI roadmap
The company’s roadmap includes Accuray Stellar for adaptive radiotherapy, Radixact as a flexible tailored solution and Accuray Helix as an entry point into the helical portfolio. It also describes AI-enabled predictive-maintenance and diagnostic tools and a 10-year collaboration with UW SMPH announced in fiscal 2026.
-
Cost base was materially reduced
Operating expenses excluding restructuring declined in several categories: research and development fell 21% to $37.753 million, selling and marketing fell 11% to $38.573 million, and general and administrative expense fell 5% to $45.398 million. The FY26 Restructuring Plan eliminated approximately 3% of employees in the September 2025 quarter and approximately 15% in the December 2025 quarter.
-
Financing actions improve near-term liquidity
The company entered into a proposed $55.0 million Series A convertible preferred financing, consisting of $15.0 million of cash and conversion of $40.0 million of existing debt. Amendment No. 3 also provides a covenant holiday through December 31, 2027, subject to closing conditions.
What to watch
-
Financing transaction may not close
The July 29, 2026 financing remains subject to stockholder approval and a 1-for-15 to 1-for-40 reverse stock split. If terminated for failure to obtain approval, the $15.0 million cash investment becomes secured debt and the company owes a fully earned, non-refundable $15.0 million fee; the contemplated $40.0 million debt exchange would also not occur.
-
Severe potential shareholder dilution
The proposed financing could materially dilute existing holders: the preferred stock currently reserves 110.0 million common shares for conversion and the company issued warrants for approximately 15.3 million common shares at a $0.01 exercise price. As of July 31, 2026, the company had 119.4 million common shares outstanding.
-
Material weakness and restatement risk
One material weakness remained unremediated as of June 30, 2026, relating to review of footnote schedules supporting financial statement disclosures. The weaknesses resulted in misstatements of remaining performance obligations and a restatement of fiscal 2025 and several quarterly periods; Grant Thornton issued an adverse opinion on internal control over financial reporting.
-
China and tariff exposure worsened
China revenue fell 45% to $68.142 million and represented 17% of total revenue, while the joint venture contributed 16% of total revenue versus 26% in the prior year. The company states that tariffs and trade uncertainty have materially reduced China product revenue and expects further China revenue reductions if tariffs escalate or persist.
-
Debt burden and covenant pressure
The company was not in compliance with the minimum liquidity covenant as of June 30, 2026, although lenders waived the default on July 29, 2026. Debt totaled $181.970 million gross, including $10.320 million of accumulated paid-in-kind interest, while annual interest expense increased to $32.905 million from $12.954 million.
-
Profitability and cash flow deteriorated
Gross margin declined to 27.7% from 32.1%, and net loss widened to $49.194 million from $1.591 million. Operating cash flow turned negative at $6.981 million, compared with $2.860 million of cash provided in the prior year, while the company expects material, freight and logistics pressure through at least fiscal 2027.
Management's outlook
No quantitative annual revenue or EPS guidance was provided in the 10-K. The company states that increased material, freight and logistics costs are expected to pressure gross margins, net income and cash from operations through at least fiscal 2027; the prior fiscal 2026 guidance had previously been withdrawn.
Earlier filings 1
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.